Emerging Healthcare Solutions completes due diligence and review requirements with ThromboVision

Emerging Healthcare Solutions, Inc. (Pink Sheets:EHSI) announced today that the company has successfully completed the due diligence and review requirements under their recent option agreement with ThromboVision, a company that has licensed the patent on the new T-Guide® Platelet Function Analyzer, which is currently going through regulatory clearance review.

Successful completion of the due diligence cleared the way for promulgation of a Term Sheet which was delivered to ThromboVision and signaled that Emerging Healthcare Solutions conferred confidence in ThromboVision’s business plan and potential products.

ThromboVision’s new T-Guide® analyzer consists of a desktop instrument and a disposable test kit that can be located at doctor’s offices and could become a front line technology that could help prevent heart attacks, strokes and stent occlusions by directly analyzing a patient’s platelet status on-site. This new technology should enable doctors to directly measure platelet status as easily as measuring cholesterol. In the US, cardiologists and primary care physicians manage 80 million cardiovascular visits each year, with over 30 million of these patients on Aspirin or Plavix® platelet therapy.

The emerging healthcare industry is expected to continue steady expansion, which could be beneficial to many cutting-edge companies such as Tenet Healthcare Corp. (NYSE: THC), Angeion Corp. (NASDAQ: ANGN), OccuLogix (NASDAQ: TEAR) and BioMimetic Therapeutics (NASDAQ: BMTI).